The high court declined to hear arguments in the dispute between Biolitec and AngioDynamics on Nov. 30, leaving Biolitec responsible for damages and contempt of court penalties that could be as high as $160 million.

A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Norway's PhotoCure is one of the few European biotech companies with a marketed product. Skin cancer photodynamic therapy Metvix PDT has already been launched in Scandinavia, and more recently by partner Galderma in Germany and the UK. Other PDT firms have struggled to educate physicians to accept a new kind of treatment-and thereby recoup the costs attached. PhotoCure is hoping that Metvix's improved efficacy and cosmetic advantages will help it create a market for PDT products.